Current Report Filing (8-k)
April 09 2015 - 6:03AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2015
ANTHERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
001-34637
|
|
20-1852016
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
25801 Industrial Boulevard, Suite B, Hayward,
California
|
|
94545
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Compensatory Arrangements of Certain Officers.
|
On April 3, 2015, as part of its annual review of compensation, our Board of Directors, upon the recommendation of the Compensation Committee, approved the annual base salaries for certain of the Company’s employees, including certain of the Company’s named executive officers, as follows:
Named Executive Officer
|
|
Effective
April 1, 2014
|
|
|
Effective
April 1, 2015
|
|
|
$ Change
|
|
Paul F. Truex, President and Chief Executive Officer
|
|
$ |
515,000 |
|
|
$ |
450,000 |
|
|
$ |
(65,000 |
) |
Colin Hislop, M.D., Senior Vice President and Chief Medical Officer
|
|
$ |
350,000 |
|
|
$ |
360,000 |
|
|
$ |
10,000 |
|
Debra Odink, Ph.D., Senior Vice President and Chief Technology Officer
|
|
$ |
340,000 |
|
|
$ |
355,000 |
|
|
$ |
15,000 |
|
Klara Dickinson, Senior Vice President and Chief Regulatory Officer (1)
|
|
$ |
- |
|
|
$ |
325,000 |
|
|
$ |
- |
|
May Liu, Senior Vice President, Finance and Administration
|
|
$ |
261,000 |
|
|
$ |
286,000 |
|
|
$ |
25,000 |
|
(1)
|
Ms. Dickinson joined the company as Senior Vice President, Chief Regulatory Officer on January 5, 2015.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 8, 2015
|
Anthera Pharmaceuticals, Inc.
|
|
|
|
|
|
By:
|
/s/ May Liu
|
|
|
May Liu
|
|
|
Principal Accounting Officer
|
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Sep 2023 to Sep 2024